EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis (EINSTEIN Jr)
Multicenter, Open-label, Active-controlled, Randomized Study to Evaluate the Efficacy and Safety of an age-and Body Weight-adjusted Rivaroxaban Regimen Compared to Standard of Care in Children With Acute Venous Thromboembolism
Sponsor: Bayer
Listed as NCT02234843, this PHASE3 trial focuses on Venous Thromboembolism and remains completed. Sponsored by Bayer, it has been updated 24 times since 2014, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
24 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Mar 2022 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2022 — Mar 2022 [monthly]
Completed PHASE3
▶ Show 19 earlier versions
-
Jan 2021 — Jan 2022 [monthly]
Completed PHASE3
-
May 2020 — Jan 2021 [monthly]
Completed PHASE3
-
Mar 2019 — May 2020 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Feb 2019 — Mar 2019 [monthly]
Active Not Recruiting PHASE3
-
Jan 2019 — Feb 2019 [monthly]
Active Not Recruiting PHASE3
-
Dec 2018 — Jan 2019 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Oct 2018 — Dec 2018 [monthly]
Recruiting PHASE3
-
Sep 2018 — Oct 2018 [monthly]
Recruiting PHASE3
-
Aug 2018 — Sep 2018 [monthly]
Recruiting PHASE3
-
Jul 2018 — Aug 2018 [monthly]
Recruiting PHASE3
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE3
-
Nov 2017 — Jun 2018 [monthly]
Recruiting PHASE3
-
Oct 2017 — Nov 2017 [monthly]
Recruiting PHASE3
-
Aug 2017 — Oct 2017 [monthly]
Recruiting PHASE3
-
Jul 2017 — Aug 2017 [monthly]
Recruiting PHASE3
-
Jun 2017 — Jul 2017 [monthly]
Recruiting PHASE3
-
Apr 2017 — Jun 2017 [monthly]
Recruiting PHASE3
-
Feb 2017 — Apr 2017 [monthly]
Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Nov 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bayer
- Janssen Research & Development, LLC
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Adana, Turkey (Türkiye) , Afula, Israel , Amsterdam, Netherlands , Atlanta, United States , Azumino, Japan , Barcelona, Spain , Beijing, China , Berlin, Germany , Bern, Switzerland and 92 more locations